PhD in Biological Sciences from the University of Valencia. Professor of the Department of Pathology of the Faculty of Medicine of the University of Valencia. She carries out his research activity at the Neurological Impairment Laboratory of the University of Valencia/INCLIVA Health Research Institute.
She coordinates the Transversal Program for Neurological Deterioration, with the participation of clinical research groups and basic research groups. She is a Member of the Training and Mobility Selection Commission, the Research Commission and the Innovation Commission of the Internal Scientific Committee of FIHCUV-INCLIVA-University of Valencia. In addition, the Euro-Mediterranean Master’s Degree in Neurosciences and Biotechnology from the University of Valencia.
Dr. Montoliu’s research activity has produced more than 120 articles published in international journals and various international patents.
We have been carrying out Basic and Translational Research with international relevance for years and we participate in the European Innovation Partnership on Active and Healthy Aging (EIP-AHA) of the European Commission, as a collaborating member.
The Neurological Impairment research group has been researching for many years mainly in the field of early detection and prevention of cognitive and functional impairment in the pathology of patients with liver disease who present minimal hepatic encephalopathy (MHE), that is, cognitive impairment and mild functional. Chronic liver disease progresses in different phases, including alcoholic or nonalcoholic liver disease and nonalcoholic steatohepatitis (NASH) that can lead to fibrosis and cirrhosis.
Our research aims to better characterize the alterations in EHM and the mechanisms that produce them, evaluating new diagnostic and therapeutic procedures. The studies are unique because they will make it possible to detect changes that are taking place in the immune system and at the brain level in patients in the earliest stages of mild cognitive and functional impairment. They will make it possible to identify brain signals or blood markers that give us information about what is happening in the brain.
Our group has been the first to find the first diagnostic marker in minimal hepatic encephalopathy and to identify a biomarker for early detection of cognitive impairment in patients with liver cirrhosis.
Early detection and treatment and prevention of cognitive and functional impairment would improve the quality of life, survival and vitality of patients with chronic liver diseases and would reduce hospitalizations and the demand for resources on the health system, improving its sustainability.
The studies of our research group will make it possible to detect changes in the process of cognitive deterioration associated with the development of pathologies such as chronic liver disease and that the results achieved contribute to improving the medical care that our health system offers to the patient. Looking for new therapeutic tools that can reverse or control the progress of cognitive and functional deterioration.